Skip to main content

Table 1 Demographic and clinical characteristics at baseline of matched cohort

From: Sugammadex is associated with shorter hospital length of stay after open lobectomy for lung cancer: a retrospective observational study

Variable Pyridostigmine (n = 127) Sugammadex (n = 127) p value
Age (year) 66.0 (59.5–71.0) 67.0 (60.0–72.0) 0.358
Male sex 92 (72.4) 96 (75.6) 0.668
Height (cm) 163.0 (159.0–168.5) 163.0 (158.0–168.0) 0.640
Weight (kg) 62.0 (56.0–67.0) 61.0 (56.0–69.5) 0.817
BMI (kg m−2) 23.1 (21.5–25.5) 23.5 (21.3–25.7) 0.445
ASA PS    0.238
 I 14 (11.0) 19 (15.0)  
 II 104 (81.9) 93 (73.2)  
 III 9 (7.1) 15 (11.8)  
Diabetes mellitus 22 (17.3) 27 (21.3) 0.525
Hypertension 55 (43.3) 55 (43.3) 1.000
CKD 5 (3.9) 2 (1.6) 0.443
Heart failure 3 (2.4) 0 (0.0) 0.245
CAD 14 (11.0) 12 (9.4) 0.836
COPD 28 (22.0) 31 (24.4) 0.766
Asthma 3 (2.4) 0 (0.0) 0.245
Operation site (right) 85 (66.9) 76 (59.8) 0.297
  1. Data are presented as n (%), median (interquartile range)
  2. BMI Body mass index, ASA PS American Society of Anesthesiologists physical status, CKD Chronic kidney disease, CAD Coronary arterial disease, COPD Chronic obstructive pulmonary disease